| Title |
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, November 2009
|
| DOI | 10.1007/s00262-009-0782-8 |
| Pubmed ID | |
| Authors |
James L. Gulley, Philip M. Arlen, Ravi A. Madan, Kwong-Yok Tsang, Mary P. Pazdur, Lisa Skarupa, Jacquin L. Jones, Diane J. Poole, Jack P. Higgins, James W. Hodge, Vittore Cereda, Matteo Vergati, Seth M. Steinberg, Susan Halabi, Elizabeth Jones, Clara Chen, Howard Parnes, John J. Wright, William L. Dahut, Jeffrey Schlom |
| Abstract |
A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC to investigate the influence of GM-CSF with vaccine, and the influence of immunologic and prognostic factors on median OS. Thirty-two patients were vaccinated once with recombinant vaccinia containing the transgenes for prostate-specific antigen (PSA) and three costimulatory molecules. Patients received boosters with recombinant fowlpox containing the same four transgenes. Twelve of 32 patients showed declines in serum PSA post-vaccination and 2/12 showed decreases in index lesions. Median OS was 26.6 months (predicted median OS by the Halabi nomogram was 17.4 months). Patients with greater PSA-specific T-cell responses showed a trend (p = 0.055) toward enhanced survival. There was no difference in T-cell responses or survival in cohorts of patients receiving GM-CSF versus no GM-CSF. Patients with a Halabi predicted survival of <18 months (median predicted 12.3 months) had an actual median OS of 14.6 months, while those with a Halabi predicted survival of > or =18 months (median predicted survival 20.9 months) will meet or exceed 37.3 months, with 12/15 patients living longer than predicted (p = 0.035). Treg suppressive function was shown to decrease following vaccine in patients surviving longer than predicted, and increase in patients surviving less than predicted. This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 50% |
| Canada | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Scientists | 2 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| China | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 109 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 23% |
| Student > Ph. D. Student | 16 | 14% |
| Student > Bachelor | 12 | 11% |
| Other | 10 | 9% |
| Student > Doctoral Student | 10 | 9% |
| Other | 27 | 24% |
| Unknown | 11 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 36% |
| Agricultural and Biological Sciences | 19 | 17% |
| Biochemistry, Genetics and Molecular Biology | 14 | 13% |
| Immunology and Microbiology | 11 | 10% |
| Mathematics | 2 | 2% |
| Other | 10 | 9% |
| Unknown | 16 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2024.
All research outputs
#3,606,320
of 23,228,787 outputs
Outputs from Cancer Immunology, Immunotherapy
#225
of 2,910 outputs
Outputs of similar age
#12,191
of 95,450 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#1
of 19 outputs
Altmetric has tracked 23,228,787 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,910 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,450 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.